What are TRIM21 antibodies?
Anti-TRIM21 antibodies are immunoglobulins that specifically recognize and bind TRIM21, the gene encoding E3 ubiquitin-protein ligase TRIM21 in humans. In research applications, these antibodies are used to detect TRIM21 in tissue samples, cell lysates, and cultured cells. TRIM21 is a cytosolic Fc receptor and E3 ubiquitin ligase that, in cooperation with E2 conjugating enzymes, targets antibody-bound intracellular pathogens and specific substrate proteins for ubiquitin-mediated degradation. Because TRIM21 is also a major autoantigen recognized in Sjogren's syndrome and lupus, it is studied in both innate immunity and autoimmune disease research.
Catalog highlights and purchasing considerations
About the Biocompare TRIM21 antibody catalog
The Biocompare antibody search tool lists TRIM21 antibodies from a wide range of suppliers, with western blot, immunoprecipitation, and immunohistochemistry among the most common validated applications. Listings may also appear under the alternate names RO52 and SSA1, reflecting TRIM21's identity as the Ro52/SS-A autoantigen. Several TRIM21 antibodies mentioned here have been cited across a range of immunology research, including studies on the ADAP-TRIM21-ZEB2 axis regulating CD8 T cell effector expansion, ceritinib-induced ferroptosis through TRIM21-mediated GLUT1 ubiquitination, and TRIM21-mediated PARP1 ubiquitination suppressing small cell lung cancer.
Considerations when choosing a TRIM21 antibody for research
Confirm that the antibody's intended target is accurate, as many genes carry synonym symbols that can create ambiguity across suppliers. Specificity should be verified against the immunogen sequence or region listed on the product datasheet, since antibodies raised against different epitopes of the same protein can behave differently across applications. Beyond specificity, several target-related attributes can affect antibody binding, including subcellular location, extracellular and cytoplasmic domain boundaries for membrane-associated targets, tissue specificity, post-translational modifications, and the presence of additional isoforms or disease-associated variants. In parallel, antibody-specific selection criteria warrant consideration, including clonality (monoclonal versus polyclonal), host species, species reactivity, and conjugate or label choice suited to the detection method. Supplier validation data, such as western blot bands at the expected molecular weight, immunohistochemistry staining patterns consistent with known tissue distribution, and knockout or knockdown controls, should also be carefully reviewed before purchase.